Shots:
- Tyra Biosciences has dosed its first patient with dabogratinib (FGFR3 inhibitor) in P-II (BEACH301) trial for the treatment achondroplasia
- Trial will evaluate dabogratinib in children (3–10 yrs) with achondroplasia & open growth plates across 2 cohorts: treatment-naïve & previously treated with growth-accelerating therapy, enrolling up to 10 pts per dose level (0.125, 0.25, 0.375 & 0.50mg/kg) in both for 12mos.; study also incl. a safety sentinel cohort of up to 3 children (5–10yrs.) per dose level
- Trial will evaluate safety & efficacy, along with change from baseline in annualized growth velocity to determine optimal dose(s) as 1EP, with 2EP incl. height z-score change, body proportionality, & PK
Ref: AbbVie | Image: AbbVie | Press Release
Related News:- AbbVie Reports Topline P-III (UP-AA) Trial Data on Rinvoq (Upadacitinib) to Treat Alopecia Areata
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
